{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:52:41Z","timestamp":1762249961277,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["2022","NCT02634307"],"award-info":[{"award-number":["2022","NCT02634307"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.msard.2024.105912","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:30:45Z","timestamp":1727677845000},"page":"105912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study"],"prefix":"10.1016","volume":"91","author":[{"given":"Samuel F.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Scaramozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Antezana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105912_bib0001","unstructured":"Biogen, 2023a. Data on file."},{"key":"10.1016\/j.msard.2024.105912_bib0002","unstructured":"Biogen, 2023b. Tecfidera Prescribing Information. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf. Accessed 9 Apr 2019."},{"key":"10.1016\/j.msard.2024.105912_bib0003","unstructured":"Biogen, 2023c. Vumerity Prescribing Information. https:\/\/www.vumerityhcp.com\/content\/dam\/commercial\/vumerity\/hcp\/en_us\/pdf\/vumerity-prescribing-information.pdf. Accessed 9 Aug 2022."},{"key":"10.1016\/j.msard.2024.105912_bib0004","unstructured":"Biogen, 2023d Vumerity Summary of product characteristics."},{"issue":"11","key":"10.1016\/j.msard.2024.105912_bib0005","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/archneur.62.11.1681","article-title":"Response to interferon beta-1a treatment in African American multiple sclerosis patients","volume":"62","author":"Cree","year":"2005","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.msard.2024.105912_bib0006","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/01.WNL.0000145762.60562.5D","article-title":"Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis","volume":"63","author":"Cree","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2024.105912_bib0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41582-022-00735-5","article-title":"Social determinants of health in multiple sclerosis","volume":"18","author":"Dobson","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.msard.2024.105912_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","article-title":"Multiple sclerosis in US minority populations: clinical practice insights","volume":"5","author":"Khan","year":"2015","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"10.1016\/j.msard.2024.105912_bib0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","article-title":"Rapid disease course in African Americans with multiple sclerosis","volume":"75","author":"Kister","year":"2010","journal-title":"Neurology"},{"issue":"6387","key":"10.1016\/j.msard.2024.105912_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aan4665","article-title":"Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity","volume":"360","author":"Kornberg","year":"2018","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.msard.2024.105912_bib0011","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1177\/1352458519881761","article-title":"Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study","volume":"26","author":"Naismith","year":"2020","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2024.105912_bib0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.msard.2024.105912_bib0013","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","article-title":"Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review","volume":"98","author":"Onuorah","year":"2022","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.msard.2024.105912_bib0014","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1073\/pnas.1603907113","article-title":"Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2","volume":"113","author":"Schulze-Topphoff","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.msard.2024.105912_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Sierra Morales","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2024.105912_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-023-00517-1","article-title":"Real-world safety and effectiveness after 5 years of dimethyl fumarate treatment in black and hispanic patients with multiple sclerosis in ESTEEM","author":"Williams","year":"2023","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.msard.2024.105912_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","article-title":"Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM","volume":"9","author":"Williams","year":"2020","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.msard.2024.105912_bib0018","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study","volume":"39","author":"Wray","year":"2022","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.msard.2024.105912_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1756285616661929","article-title":"Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis","volume":"9","author":"Zhovtis Ryerson","year":"2016","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:31:29Z","timestamp":1732336289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":19,"alternative-id":["S2211034824004887"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105912","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105912"}}